Eyenovia acquires US licencing rights for Formosa’s topical eye steroid

16 Aug 2023
www.pharmaceutical-technology.com
Drug ApprovalNDALicense out/in
Eyenovia acquires US licencing rights for Formosa’s topical eye steroid
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Eyenovia acquires US licencing rights for Formosa’s topical eye steroid
Preview
Source: Pharmaceutical Technology
Formosa will receive up to $86m, in upfront and milestone-based payments. Image Credit: megaflopp / Shutterstock.
Eyenovia has acquired the exclusive licencing and commercialisation rights for APP13007 (clobetasol steroid) in the US, from the Taiwan-based Formosa Pharmaceuticals for $86m.
The deal builds upon the existing partnership between the two companies to develop new eye therapies signed earlier this year.
Recommended Reports
Eyenovia acquires US licencing rights for Formosa’s topical eye steroid
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Clobetasol Propionate in Ocular Pain (Eye Pain) GlobalData
Eyenovia acquires US licencing rights for Formosa’s topical eye steroid
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Tafenoquine Succinate in Candidiasis GlobalData
View allCompanies IntelligenceEyenovia IncAimMax Therapeutics IncFormosaView all
APP13007 is a 0.05% clobetasol propionate ophthalmic nanosuspension developed using Formosa’s proprietary APNT nanoparticle formulation platform by Formosa and AimMax Therapeutics. It is a twice-daily topical corticosteroid that reduces pain and inflammation following eye surgery.
APP13007 is currently under review by the US Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date set for 4 March 2024.
Following the FDA approval and transfer of the New Drug Application (NDA) to Eyenovia, Formosa will be eligible to receive a single-digit million-dollar payment, as per Eyenovia’s 16 August press release. Formosa will receive additional milestone-based payments totalling $86m, including the upfront payment.
Eyenovia plans to incorporate the drug with its drug delivery device Optejet for a drug-device therapeutic, with the company’s CEO Michael Rowe stating: “We will also be discussing with the FDA the opportunity to develop novel clobetasol formulations as a late-stage asset for use with the Optejet as a potential treatment for dry eye, a market estimated to be worth over $3.6 billion.”
Earlier this year, Eyenovia’s MydCombi (tropicamide and phenylephrine hydrochloride) was the first eye spray approved by the US FDA for pupil dilation. The spray can be used for pupillary dilation in multiple conditions including cataracts and other eye surgeries.
Eyenovia plans to market both products for surgical use. “Alongside our mydriasis product, MydCombi, we can bring additional value to ophthalmic surgeons and their patients through the use of MydCombi for pre-operative dilation and APP13007 post-operatively, both supported by a single dedicated sales force,” said Rowe.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.